Keros Therapeutics (NASDAQ:KROS – Get Free Report) had its price target lowered by stock analysts at Leerink Partners from $30.00 to $23.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. Zacks Research lowered Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 29th. Get Keros Therapeutics alerts:Get Our Latest Stock Analysis on Keros TherapeuticsKeros Therapeutics Stock PerformanceKeros Therapeutics stock opened at $10.11 on Tuesday. Keros Therapeutics (NASDAQ:KROS – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. Further ReadingReceive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.